2023
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson S, Gregg I, Dibbs M, Liao C, Wu H, Davoudian P, Woodburn S, Wehrle P, Sprouse J, Sherwood A, Kaye A, Pittenger C, Kwan A. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology 2023, 48: 1257-1266. PMID: 37015972, PMCID: PMC10354037, DOI: 10.1038/s41386-023-01572-w.Peer-Reviewed Original ResearchConceptsMouse medial frontal cortexEarly phase clinical studiesDendritic spine densityHead-twitch responseDose-dependent increaseStructural neural plasticityMedial frontal cortexSpine densityClinical studiesFrontal cortexLong-term effectsDendritic spinesMental illnessNeural plasticitySpine formationPatient accessSubjective effectsNeural consequencesPotential therapeuticsSerotonergic psychedelicsAnxiety symptomsNeural mechanismsUltrasonic vocalizationsElevated ratesMice
2020
Novel Therapies for Glioblastoma
Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.Peer-Reviewed Original ResearchConceptsClinical studiesEarly phase clinical studiesNovel radiotherapy approachesSignificant survival benefitMalignant primary brain tumorPhase clinical studiesPersonalized treatment approachesDiverse resistance mechanismsPrimary brain tumorCheckpoint inhibitionRadiotherapy optionsRadiotherapy approachesDose deliveryRadiation modalitiesSurvival benefitBiomarker-drivenTargeted therapyTargeted agentsTreatment optionsNovel therapiesTumor heterogeneityClinical investigationVaccination strategiesBrain tumorsTreatment approaches
2018
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial
Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75: 11-19. PMID: 29167877, PMCID: PMC5833531, DOI: 10.1001/jamapsychiatry.2017.3572.Peer-Reviewed Original ResearchConceptsTarget engagement biomarkerKetamine infusionClinical trialsClinical studiesEarly-stage clinical studiesEarly phase clinical studiesTarget engagementFunctional target engagementRecent pivotal trialsFMRI responsesBlood oxygen level-dependent (BOLD) responseUtility of imagingProton magnetic resonance spectroscopySufficient effect sizeLevel-dependent responsesPlacebo infusionPivotal trialsPreclinical evidenceEngagement biomarkersKetamine effectsMean ageBrain glutamateHealthy volunteersMAIN OUTCOMEPsychiatric history
2011
OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740. Cancer Research 2011, 71: ot3-01-03-ot3-01-03. DOI: 10.1158/0008-5472.sabcs11-ot3-01-03.Peer-Reviewed Original ResearchPre-surgical studyInvasive breast cancerBreast cancerPI3K/AktWeekly MKPost-treatment tissue samplesOperable invasive breast cancerPeripheral blood mononuclear cellsEarly phase clinical studiesDownstream PI3K/Akt pathwayClinical stage IClinical trial programBlood mononuclear cellsMain eligibility criteriaPre-surgical evaluationEarly clinical testingPI3K/Akt pathwayEffects of MKAKT inhibitor MKPost-treatment samplesAnti-cancer propertiesParaffin-embedded tissuesAccrue patientsAnti-cancer agentsNeoadjuvant chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply